0 CHECKOUT
Global Preventive Asthma Drugs Market 2015-2019 - Product Image

Global Preventive Asthma Drugs Market 2015-2019

  • ID: 3446394
  • October 2015
  • Region: Global
  • 81 pages
  • TechNavio
1 of 5

FEATURED COMPANIES

  • Abbott
  • Biotest
  • Dainippon Sumitomo
  • Merck
  • Pfizer
  • Sunovion
  • MORE

About asthma
According to the Global Initiative for Asthma, asthma is a chronic disease, which is characterized by wheezing, shortness of breath, chest tightness, and cough over a period of time. The symptoms worsen due to the increased secretion of mucus, bronchoconstriction, and thickening of the walls of the airways, resulting in difficulty in expiration. According to the American Academy of Allergy, Asthma, and Immunology, asthma is classified into four types: exercise-induced, allergic, occupational, and childhood. Also, asthma can be classified into two categories: allergic and non-allergic, as per the classification of Asthma and Allergy Foundation of America. Asthma can be managed by preventive medications, which should be administered to the patient regularly to improve his quality of life by controlling the exacerbations.

The report forecasts the global preventive asthma drugs market to grow at a CAGR of 5.20% over the period 2014-2019.

Covered in this report
This report covers the present scenario and the growth prospects of the global preventive asthma drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from READ MORE >

Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott
  • Biotest
  • Dainippon Sumitomo
  • Merck
  • Pfizer
  • Sunovion
  • MORE

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Product profiles
Accolate
Pulmicort
Symbicort
Xolair
Advair
Anoro Ellipta
Arnuity Ellipta
Breo Ellipta
Flovent
Serevent
Ventolin
Asmanex
Foradil
Dulera
Singulair

PART 06: Disease overview
Understanding the disease
Symptoms
Pathophysiology
Epidemiology
Diagnosis
Management

PART 07: Pipeline Portfolio

PART 08: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 09: Market segmentation by class of drug

PART 10: ICS/LABA combination
Global ICS/LABA combination market

PART 11: Immuno-suppressants
Global immunosuppressants market

PART 12: Leukotriene antagonists
Global leukotriene antagonists market

PART 13: Mast cell stabilizers
Global mast cell stabilizers market

PART 14: Inhaled corticosteroids
Global inhaled corticosteroids market

PART 15: Geographical segmentation
Global preventive asthma drugs market by geography 2014-2019
Preventive asthma drugs market in Americas
Preventive asthma drugs market in EMEA
Preventive asthma drugs market in APAC

PART 16: Market drivers

PART 17: Impact of drivers

PART 18: Market challenges

PART 19: Impact of drivers and challenges

PART 20: Market trends

PART 21: Vendor landscape
Competitive scenario
Other and future prominent vendors

PART 22: Key vendor analysis
AstraZeneca
F. Hoffmann-La Roche
GlaxoSmithKline
Merck
Novartis

PART 23: Appendix
List of abbreviations

PART 24: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Major diagnostic procedures for asthma
Exhibit 03: Major drugs under development for asthma
Exhibit 04: Global preventive asthma drugs market ($ millions)
Exhibit 05: Five forces analysis
Exhibit 06: Segmentation of global preventive asthma drugs market by class of drug
Exhibit 07: Segmentation of global preventive asthma drugs market by class of drug 2014
Exhibit 08: Global preventive asthma drugs market: Market share by class of drug 2014-2019 ($ millions)
Exhibit 09: Global ICS/LABA combination market 2014-2019 ($ millions)
Exhibit 10: Global immunosuppressants market 2014-2019 ($ millions)
Exhibit 11: Global leukotriene antagonists market 2014-2019 ($ millions)
Exhibit 12: Global mast cell stabilizers market 2014-2019 ($ millions)
Exhibit 13: Global corticosteroids market 2014-2019 ($ millions)
Exhibit 14: Global preventive asthma drugs market by geography 2014
Exhibit 15: Global preventive asthma drugs market: Market share by region 2014-2019 ($ millions)
Exhibit 16: Preventive asthma drugs market in Americas 2014-2019 ($ millions)
Exhibit 17: Preventive asthma drugs market in EMEA 2014-2019 ($ millions)
Exhibit 18: Impact of drivers
Exhibit 19: Impact of drivers and challenges
Exhibit 20: Sales of Pulmicort in US 2011-2014 ($ millions)
Exhibit 21: Global sales of Pulmicort 2011-2014 ($ millions)
Exhibit 22: AstraZeneca: Key takeaways
Exhibit 23: Sales of Xolair in the US 2011-2014 ($ millions)
Exhibit 24: F. Hoffmann-La Roche: Key takeaways
Exhibit 25: Global sales of Ventolin 2011-2014 ($ millions)
Exhibit 26: Global sales of Flovent 2011-2014 ($ millions)
Exhibit 27: Global sales of Advair 2011-2014 ($ millions)
Exhibit 28: Global sales of Serevent 2011-2014 ($ millions)
Exhibit 29: GlaxoSmithKline: Key takeaways
Exhibit 30: Global sales of Asmanex 2011-2013 ($ millions)
Exhibit 31: Global sales of Dulera 2011-2013 ($ millions)
Exhibit 32: Global sales of Singulair 2011-2013 ($ millions)
Exhibit 33: Merck: Key takeaways
Exhibit 34: Sales of Xolair (ex-US) 2011-2014 ($ millions)
Exhibit 35: Key takeaways: Novartis
Exhibit 36: AstraZeneca: Business segmentation by revenue 2014
Exhibit 37: AstraZeneca: Business segmentation by revenue 2013 and 2014
Exhibit 38: AstraZeneca: Geographical segmentation by revenue 2014

Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • Abbott
  • Biotest
  • Dainippon Sumitomo
  • Merck
  • Pfizer
  • Sunovion
  • MORE

New Report Released: – Global Preventive Asthma Drugs Market 2015-2019

The author of the report recognizes the following companies as the key players in the Global Preventive Asthma Drugs Market: AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, Merck and Novartis

Other Prominent Vendors in the market are: Abbott, Amgen, AptarGroup, Biotest, Boehringer Ingelheim, Chiesi Farmaceutici, Cytos, Dainippon Sumitomo, Medicinova, Mylan, Novartis, Orchid Chemicals and Pharmaceuticals, Pfizer, Rottapharm Madaus, Skyepharma, Sosei, Sunovion, Teva Pharmaceutical, Theravance, Vectura

Commenting on the report, an analyst from the research team said: “The popularity of combination therapies for the treatment of asthma will help in the market's growth. Drugs that fall under the category of ICS, LABA, and leukotriene receptor antagonists are frequently prescribed by physicians to control asthma.”

According to the report, the market is set to grow because of the high prevalence of asthma worldwide. The demand for drugs to treat and prevent asthma presents an opportunity to develop a therapy with better efficacy and safety profiles. The market expects to launch its robust pipeline of drug candidates for the management of asthma during the forecast period.

Further, the report states that growth may be hampered because of the disease's unknown origins. Finding a drug that targets the root cause of the disease has been difficult to find. Also, the patent expiry of some of the highest-selling drugs has resulted in the entry of generics, affecting market growth.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Note: Product cover images may vary from those shown
4 of 5

- AstraZeneca
- F. Hoffmann-La Roche
- GlaxoSmithKline
- Merck
- Novartis
- Abbott
- Amgen
- AptarGroup
- Biotest
- Boehringer Ingelheim
- Chiesi Farmaceutici
- Cytos
- Dainippon Sumitomo
- Medicinova
- Mylan
- Novartis
- Orchid Chemicals and Pharmaceuticals
- Pfizer
- Rottapharm Madaus
- Skyepharma
- Sosei
- Sunovion
- Teva Pharmaceutical
- Theravance
- Vectura

Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-5 user licence, allowing up to five users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Sanofi S.A.
  • GlaxoSmithKline PLC
  • Astrazeneca PLC
  • Invacare Corporation
  • Boehringer Ingelheim GmbH
  • Takeda Pharmaceutical Company Limited